<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Alzecure Pharma Ab — News on 6ix</title>
<link>https://6ix.com/company/alzecure-pharma-ab</link>
<description>Latest news and press releases for Alzecure Pharma Ab on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Mon, 20 Apr 2026 08:20:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/alzecure-pharma-ab" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo69d5624abeedb30cb6f7f99f.webp</url>
<title>Alzecure Pharma Ab</title>
<link>https://6ix.com/company/alzecure-pharma-ab</link>
</image>
<item>
<title>Last Patient has Completed AlzeCure's Phase Ib Clinical Study with NeuroRestore ACD856</title>
<link>https://6ix.com/company/alzecure-pharma-ab/news/last-patient-has-completed-alzecures-phase-ib-clinical-study-with-neurorestore-acd856</link>
<guid isPermaLink="true">https://6ix.com/company/alzecure-pharma-ab/news/last-patient-has-completed-alzecures-phase-ib-clinical-study-with-neurorestore-acd856</guid>
<pubDate>Mon, 20 Apr 2026 08:20:00 GMT</pubDate>
<description>STOCKHOLM, SE / ACCESS Newswire / April 20, 2026 / AlzeCure Pharma AB (publ) (STO:ALZCUR)(FRA:AC6), a biotech company that develops candidate drugs for diseases affecting the nervous system, focusing on Alzheimer's disease and pain, today announced ...</description>
</item>
<item>
<title>AlzeCure Pharma Publishes its Annual Report for 2025</title>
<link>https://6ix.com/company/alzecure-pharma-ab/news/alzecure-pharma-publishes-its-annual-report-for-2025</link>
<guid isPermaLink="true">https://6ix.com/company/alzecure-pharma-ab/news/alzecure-pharma-publishes-its-annual-report-for-2025</guid>
<pubDate>Wed, 08 Apr 2026 06:15:00 GMT</pubDate>
<description>STOCKHOLM, SE / ACCESS Newswire / April 8, 2026 / AlzeCure Pharma AB (publ) (STO:ALZCUR)(FRA:AC6), a biotech company that develops candidate drugs for diseases affecting the nervous system, focusing on Alzheimer's disease and pain, today announced ...</description>
</item>
<item>
<title>AlzeCure Pharma to Present at Redeye Healthcare Day on April 14</title>
<link>https://6ix.com/company/alzecure-pharma-ab/news/alzecure-pharma-to-present-at-redeye-healthcare-day-on-april-14</link>
<guid isPermaLink="true">https://6ix.com/company/alzecure-pharma-ab/news/alzecure-pharma-to-present-at-redeye-healthcare-day-on-april-14</guid>
<pubDate>Tue, 07 Apr 2026 08:20:00 GMT</pubDate>
<description>STOCKHOLM, SE / ACCESS Newswire / April 7, 2026 / AlzeCure Pharma AB (publ) (STO:ALZCUR)(FRA:AC6), a biotech company that develops candidate drugs for diseases affecting the nervous system, focusing on Alzheimer's disease and pain, today announced ...</description>
</item>
<item>
<title>AlzeCure Pharma to Present at Redeye Alzheimer's Theme Event on April 9</title>
<link>https://6ix.com/company/alzecure-pharma-ab/news/alzecure-pharma-to-present-at-redeye-alzheimers-theme-event-on-april-9</link>
<guid isPermaLink="true">https://6ix.com/company/alzecure-pharma-ab/news/alzecure-pharma-to-present-at-redeye-alzheimers-theme-event-on-april-9</guid>
<pubDate>Wed, 01 Apr 2026 08:15:00 GMT</pubDate>
<description>STOCKHOLM, SE / ACCESS Newswire / April 1, 2026 / AlzeCure Pharma AB (publ) (STO:ALZCUR)(FRA:AC6), a biotech company that develops candidate drugs for diseases affecting the nervous system, focusing on Alzheimer's disease and pain, today announced ...</description>
</item>
<item>
<title>AlzeCure Presents New Preclinical Data with NeuroRestore ACD856 at the Alzheimer's Conference AD/PD</title>
<link>https://6ix.com/company/alzecure-pharma-ab/news/alzecure-presents-new-preclinical-data-with-neurorestore-acd856-at-the-alzheimers-conference-adpd</link>
<guid isPermaLink="true">https://6ix.com/company/alzecure-pharma-ab/news/alzecure-presents-new-preclinical-data-with-neurorestore-acd856-at-the-alzheimers-conference-adpd</guid>
<pubDate>Thu, 19 Mar 2026 07:15:00 GMT</pubDate>
<description>STOCKHOLM, SE / ACCESS Newswire / March 19, 2026 / AlzeCure Pharma AB (publ) (STO:ALZCUR)(FRA:AC6), a pharmaceutical company that develops candidate drugs for diseases affecting the nervous system, focusing on Alzheimer's disease and pain, today announced ...</description>
</item>
<item>
<title>AlzeCure Pharma to Present at Stora Aktiedagarna in Stockholm on March 11</title>
<link>https://6ix.com/company/alzecure-pharma-ab/news/alzecure-pharma-to-present-at-stora-aktiedagarna-in-stockholm-on-march-11-1</link>
<guid isPermaLink="true">https://6ix.com/company/alzecure-pharma-ab/news/alzecure-pharma-to-present-at-stora-aktiedagarna-in-stockholm-on-march-11-1</guid>
<pubDate>Wed, 04 Mar 2026 09:15:00 GMT</pubDate>
<description>STOCKHOLM, SE / ACCESS Newswire / March 4, 2026 / AlzeCure Pharma AB (publ) (STO:ALZCUR)(FRA:AC6), a biotech company that develops candidate drugs for diseases affecting the nervous system, focusing on Alzheimer's disease and pain, today announced ...</description>
</item>
<item>
<title>AlzeCure Publishes its Year-End Report for January - December 2025</title>
<link>https://6ix.com/company/alzecure-pharma-ab/news/alzecure-publishes-its-year-end-report-for-january-december-2025-1</link>
<guid isPermaLink="true">https://6ix.com/company/alzecure-pharma-ab/news/alzecure-publishes-its-year-end-report-for-january-december-2025-1</guid>
<pubDate>Thu, 26 Feb 2026 07:25:00 GMT</pubDate>
<description>STOCKHOLM, SE / ACCESS Newswire / February 26, 2026 / AlzeCure Pharma AB (publ) (STO:ALZCUR)(FRA:AC6) today announced that its Year-end report for the period January - December 2025 is now available on the company's website: www.alzecurepharma.com/en/section/investors/financial-reports/ ...</description>
</item>
<item>
<title>Pain Project ACD440 Granted Orphan Drug Status in the EU</title>
<link>https://6ix.com/company/alzecure-pharma-ab/news/pain-project-acd440-granted-orphan-drug-status-in-the-eu</link>
<guid isPermaLink="true">https://6ix.com/company/alzecure-pharma-ab/news/pain-project-acd440-granted-orphan-drug-status-in-the-eu</guid>
<pubDate>Tue, 24 Feb 2026 12:00:00 GMT</pubDate>
<description>STOCKHOLM, SE / ACCESS Newswire / February 24, 2026 / AlzeCure Pharma AB (publ) (FN STO:ALZCUR)(STO:ALZCUR)(FRA:AC6), a biotech company that develops candidate drugs for diseases affecting the nervous system, focusing on Alzheimer's disease and pain, ...</description>
</item>
<item>
<title>AlzeCure Abstract on NeuroRestore ACD856 accepted at the Alzheimer's conference AP/PD 2026</title>
<link>https://6ix.com/company/alzecure-pharma-ab/news/alzecure-abstract-on-neurorestore-acd856-accepted-at-the-alzheimers-conference-appd-2026</link>
<guid isPermaLink="true">https://6ix.com/company/alzecure-pharma-ab/news/alzecure-abstract-on-neurorestore-acd856-accepted-at-the-alzheimers-conference-appd-2026</guid>
<pubDate>Tue, 03 Feb 2026 09:15:00 GMT</pubDate>
<description>STOCKHOLM, SE / ACCESS Newswire / February 3, 2026 / AlzeCure Pharma AB (publ) (FN STO:ALZCUR)(STO:ALZCUR)(FRA:AC6), a pharmaceutical company that develops candidate drugs for diseases affecting the nervous system, focusing on Alzheimer's disease ...</description>
</item>
<item>
<title>AlzeCure Pharma Selected to Present at the Bio-Neuroscience conference in Amsterdam</title>
<link>https://6ix.com/company/alzecure-pharma-ab/news/alzecure-pharma-selected-to-present-at-the-bio-neuroscience-conference-in-amsterdam</link>
<guid isPermaLink="true">https://6ix.com/company/alzecure-pharma-ab/news/alzecure-pharma-selected-to-present-at-the-bio-neuroscience-conference-in-amsterdam</guid>
<pubDate>Mon, 02 Feb 2026 12:15:00 GMT</pubDate>
<description>STOCKHOLM, SE / ACCESS Newswire / February 2, 2026 / AlzeCure Pharma AB (publ) (FN STO:ALZCUR)(FRA:AC6), a biotech company that develops candidate drugs for diseases affecting the nervous system, focusing on Alzheimer's disease and pain, today announced ...</description>
</item>
<item>
<title>AlzeCure Receives Payment of EU Grant for Phase 2 Clinical Trial with NeuroRestore ACD856 for Alzheimer's Disease</title>
<link>https://6ix.com/company/alzecure-pharma-ab/news/alzecure-receives-payment-of-eu-grant-for-phase-2-clinical-trial-with-neurorestore-acd856-for-alzheimers-disease-1</link>
<guid isPermaLink="true">https://6ix.com/company/alzecure-pharma-ab/news/alzecure-receives-payment-of-eu-grant-for-phase-2-clinical-trial-with-neurorestore-acd856-for-alzheimers-disease-1</guid>
<pubDate>Wed, 03 Dec 2025 09:15:00 GMT</pubDate>
<description>STOCKHOLM, SE / ACCESS Newswire / December 3, 2025 / AlzeCure Pharma AB (publ) (STO:ALZCUR)(FRA:AC6), a pharmaceutical company that develops candidate drugs for diseases affecting the nervous system, focusing on Alzheimer's disease and pain, announced ...</description>
</item>
<item>
<title>AlzeCure Publishes its Interim Report for January - September 2025</title>
<link>https://6ix.com/company/alzecure-pharma-ab/news/alzecure-publishes-its-interim-report-for-january-september-2025-1</link>
<guid isPermaLink="true">https://6ix.com/company/alzecure-pharma-ab/news/alzecure-publishes-its-interim-report-for-january-september-2025-1</guid>
<pubDate>Tue, 11 Nov 2025 07:15:00 GMT</pubDate>
<description>STOCKHOLM, SE / ACCESS Newswire / November 11, 2025 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) - AlzeCure Pharma AB (publ) (FN STO:ALZCUR) today announced that its interim report for the period January - September 2025 is now available on the company's ...</description>
</item>
<item>
<title>AlzeCure Pharma to Present at Redeye Neurology Day on October 15</title>
<link>https://6ix.com/company/alzecure-pharma-ab/news/alzecure-pharma-to-present-at-redeye-neurology-day-on-october-15-1</link>
<guid isPermaLink="true">https://6ix.com/company/alzecure-pharma-ab/news/alzecure-pharma-to-present-at-redeye-neurology-day-on-october-15-1</guid>
<pubDate>Tue, 07 Oct 2025 08:00:00 GMT</pubDate>
<description>STOCKHOLM, SE / ACCESS Newswire / October 7, 2025 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) - AlzeCure Pharma AB (publ) (FN STO:ALZCUR), a pharmaceutical company that develops candidate drugs for diseases affecting the nervous system, focusing on Alzheimer's ...</description>
</item>
<item>
<title>Positive Study Results with TrkA-NAM ACD137 Against Knee Osteoarthritis Presented at Pain Conference NeuPSIG 2025</title>
<link>https://6ix.com/company/alzecure-pharma-ab/news/positive-study-results-with-trka-nam-acd137-against-knee-osteoarthritis-presented-at-pain-conference-neupsig-2025-1</link>
<guid isPermaLink="true">https://6ix.com/company/alzecure-pharma-ab/news/positive-study-results-with-trka-nam-acd137-against-knee-osteoarthritis-presented-at-pain-conference-neupsig-2025-1</guid>
<pubDate>Mon, 08 Sep 2025 08:20:00 GMT</pubDate>
<description>STOCKHOLM, SE / ACCESS Newswire / September 8, 2025 / AlzeCure Pharma AB (publ) (FN STO:ALZCUR), a pharmaceutical company that develops candidate drugs for diseases affecting the nervous system, focusing on Alzheimer's disease and pain, today announced ...</description>
</item>
<item>
<title>Data from AlzeCure's Pain Project ACD440 Presented at the NeuPSIG 2025 Pain Conference</title>
<link>https://6ix.com/company/alzecure-pharma-ab/news/data-from-alzecures-pain-project-acd440-presented-at-the-neupsig-2025-pain-conference-1</link>
<guid isPermaLink="true">https://6ix.com/company/alzecure-pharma-ab/news/data-from-alzecures-pain-project-acd440-presented-at-the-neupsig-2025-pain-conference-1</guid>
<pubDate>Thu, 04 Sep 2025 08:20:00 GMT</pubDate>
<description>STOCKHOLM, SE / ACCESS Newswire / September 4, 2025 / AlzeCure Pharma AB (publ) (FN STO:ALZCUR), a pharmaceutical company that develops candidate drugs for diseases affecting the nervous system, focusing on Alzheimer's disease and pain, today announced ...</description>
</item>
<item>
<title>AlzeCure Publishes its Interim Report for January - June 2025</title>
<link>https://6ix.com/company/alzecure-pharma-ab/news/alzecure-publishes-its-interim-report-for-january-june-2025-1</link>
<guid isPermaLink="true">https://6ix.com/company/alzecure-pharma-ab/news/alzecure-publishes-its-interim-report-for-january-june-2025-1</guid>
<pubDate>Tue, 26 Aug 2025 06:20:00 GMT</pubDate>
<description>STOCKHOLM, SE / ACCESS Newswire / August 26, 2025 / AlzeCure Pharma AB (publ) (FN STO:ALZCUR) today announced that its interim report for the period January - June 2025 is now available on the company's website: www.alzecurepharma.com/en/section/investors/financial-reports/ ...</description>
</item>
<item>
<title>AlzeCure Appoints Cecilia Wadell as New Head of Development</title>
<link>https://6ix.com/company/alzecure-pharma-ab/news/alzecure-appoints-cecilia-wadell-as-new-head-of-development-1</link>
<guid isPermaLink="true">https://6ix.com/company/alzecure-pharma-ab/news/alzecure-appoints-cecilia-wadell-as-new-head-of-development-1</guid>
<pubDate>Wed, 20 Aug 2025 08:20:00 GMT</pubDate>
<description>STOCKHOLM, SE / ACCESS Newswire / August 20, 2025 / AlzeCure Pharma AB (publ) (FN STO:ALZCUR), a pharmaceutical company that develops candidate drugs for diseases affecting the nervous system, focusing on Alzheimer's disease and pain, has appointed ...</description>
</item>
<item>
<title>AlzeCure Pharma Livestreams Event about The Pain Project ACD440 and The Opportunities Within Orphan Drugs</title>
<link>https://6ix.com/company/alzecure-pharma-ab/news/alzecure-pharma-livestreams-event-about-the-pain-project-acd440-and-the-opportunities-within-orphan-drugs-1</link>
<guid isPermaLink="true">https://6ix.com/company/alzecure-pharma-ab/news/alzecure-pharma-livestreams-event-about-the-pain-project-acd440-and-the-opportunities-within-orphan-drugs-1</guid>
<pubDate>Tue, 19 Aug 2025 08:20:00 GMT</pubDate>
<description>STOCKHOLM, SE / ACCESS Newswire / August 19, 2025 / AlzeCure Pharma AB (publ) (FN STO:ALZCUR), a pharmaceutical company that develops candidate drugs for diseases affecting the nervous system, focusing on Alzheimer's disease and pain, invites you ...</description>
</item>
<item>
<title>New Scientific Data with TrkA-NAM ACD137 Against Knee Osteoarthritis to be Presented at Pain Conference</title>
<link>https://6ix.com/company/alzecure-pharma-ab/news/new-scientific-data-with-trka-nam-acd137-against-knee-osteoarthritis-to-be-presented-at-pain-conference-1</link>
<guid isPermaLink="true">https://6ix.com/company/alzecure-pharma-ab/news/new-scientific-data-with-trka-nam-acd137-against-knee-osteoarthritis-to-be-presented-at-pain-conference-1</guid>
<pubDate>Tue, 05 Aug 2025 08:20:00 GMT</pubDate>
<description>STOCKHOLM, SE / ACCESS Newswire / August 5, 2025 / AlzeCure Pharma AB (publ) (FN STO:ALZCUR), a pharmaceutical company that develops candidate drugs for diseases affecting the nervous system, focusing on Alzheimer's disease and pain, today announced ...</description>
</item>
<item>
<title>New Scientific Article Published on Positive Clinical Results with Painless ACD440 Against Neuropathic Pain</title>
<link>https://6ix.com/company/alzecure-pharma-ab/news/new-scientific-article-published-on-positive-clinical-results-with-painless-acd440-against-neuropathic-pain-1</link>
<guid isPermaLink="true">https://6ix.com/company/alzecure-pharma-ab/news/new-scientific-article-published-on-positive-clinical-results-with-painless-acd440-against-neuropathic-pain-1</guid>
<pubDate>Tue, 29 Jul 2025 06:20:00 GMT</pubDate>
<description>STOCKHOLM, SE / ACCESS Newswire / July 29, 2025 / AlzeCure Pharma AB (publ) (FN STO:ALZCUR), a pharmaceutical company that develops candidate drugs for diseases affecting the nervous system, focusing on Alzheimer's disease and pain, today announced ...</description>
</item>
</channel>
</rss>